SORT BY PROGRAM


Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection

Publication Date
October 26, 2022

Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment

Publication Date
August 3, 2022

In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain

Publication Date
March 15, 2022

Activity of cefepime-taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19

Publication Date
February 7, 2022

Clinical exposure–response relationship of cefepime-taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model

Publication Date
November 8, 2021

Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor

Publication Date
October 18, 2021

The Next-Generation β-Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing Escherichia coli

Publication Date
September 8, 2021

Activity of Cefepime in Combination with the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-β-Lactamase-Producing Isolates in In Vitro Checkerboard Assays

Publication Date
March 18, 2021

Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1Q119X mutants, and in vitro activity of cefepime/taniborbactam against MBLs producing Enterobacterales

Publication Date
November 24, 2020

Activity of beta-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria

Publication Date
October 9, 2020

Metallo-Beta-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline

Publication Date
September 21, 2020

In vivo pharmacodynamics of new-generation beta-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-beta-lactamase-producing Gram-negative bacteria

Publication Date
August 30, 2020

In vitro activity of the novel beta-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China

Publication Date
July 15, 2020

VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-Beta-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa

Publication Date
December 23, 2019

Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-Beta-Lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections

Publication Date
November 25, 2019

Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases

Publication Date
August 27, 2019

Interplay between beta-lactamases and new beta-lactamase inhibitors

Publication Date
March 5, 2019